AstraZeneca buys U.S. lung drug firm Pearl for up to $1.15 billion
For what it is worth.
From the news release;
"....it will pay an initial $560 million plus up to $450 million if certain development milestones are hit as well as sales-related payments of up to a further $140 million. Pearl's lead product, PT003 is in final-stage Phase III clinical trials. The acquisition, which is expected to close in the third quarter of 2013, will have no impact on AstraZeneca's financial guidance for the year, the drugmaker said."
Pearl has no approved drug. If TLON does partner MTL we should get a pretty good up front payment.
Naturally, a good German NHL trial will add to the value of Marqibo. Combining both MTL and Marquibo should put the acquisition price of TLON in the billions.